Logo

Janssen's Darzalex (daratumumab) Combination Regimen Receives EC's Approval for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Share this

Janssen's Darzalex (daratumumab) Combination Regimen Receives EC's Approval for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Shots:

  • The approval is based on P-III CASSIOPEIA studyassessingDarzalex + bortezomib- thalidomide and dexamethasone (VTd) vs VTd in 1085 newly diagnosed patients with previously untreated- symptomatic MM- who were eligible for high-dose CT and stem cell transplant
  • The P-III CASSIOPEIA study results: higher sCR (29% vs 20%); @18.8mos. improvement in PFS (93% vs 85%)- published in The Lancet in Jun’2019 and at ASCO2019. The approval marks the sixth approval for Darzalex and the third in the frontline setting
  • Darzalex is a CD38-directed antibody and is an approved therapy as monothx. or in combination with other drugs in multiple countries including the US for MM. In Aug’2012- Genmab granted exclusive rights of Darzalex to Janssen

Click here ­to­ read full press release/ article 

Ref: Business wire  | Image: Janssen


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions